Journey Medical (DERM)
(Delayed Data from NSDQ)
$5.47 USD
+0.01 (0.18%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $5.47 0.00 (0.00%) 6:48 PM ET
3-Hold of 5 3
C Value D Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$5.47 USD
+0.01 (0.18%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $5.47 0.00 (0.00%) 6:48 PM ET
3-Hold of 5 3
C Value D Growth B Momentum D VGM
Zacks News
Dermira (DERM) Gains 5% in a Week, Post-Qbrexa Approval
by Zacks Equity Research
Shares of Dermira, Inc. (DERM) increase about 5% after the FDA approved its excessive underarm sweating drug, Qbrexza.
Are Options Traders Betting on a Big Move in Dermira (DERM) Stock?
by Zacks Equity Research
Investors in Dermira (DERM) need to pay close attention to the stock based on moves in the options market lately.
Dermira's Acne Candidate Fails in Pivotal Trials, Shares Sink
by Zacks Equity Research
Dermira's (DERM) pipeline candidate, olumacostat glasaretil, fails to meet primary endpoints in two pivotal studies, which evaluate its efficacy for treating moderate-to-severe acne vulgaris.
Are Options Traders Betting on a Big Move in Dermira (DERM) Stock?
by Zacks Equity Research
Investors in Dermira (DERM) need to pay close attention to the stock based on moves in the options market lately.
Are Options Traders Betting on a Big Move in Dermira (DERM) Stock?
by Zacks Equity Research
Investors in Dermira (DERM) need to pay close attention to the stock based on moves in the options market lately.
Dermira, Inc. (DERM) Soars: Stock Adds 5.3% in Session
by Zacks Equity Research
Dermira, Inc. (DERM) saw its shares rise over 5% on the day.